{
  "docId": "019de076-b5af-740f-a5f5-cc716fe64761",
  "docSlug": "e5f34198aff4080f2687fe569caff4c0",
  "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides",
  "authorId": "neurosense-therapeutics",
  "authorName": "NeuroSense Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 17,
  "pageCount": 33,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "traction",
  "function": "show_traction",
  "density": "balanced",
  "nDataPoints": 3,
  "notes": "The slide highlights a statistically significant 37.4% reduction in disease progression for the Per Protocol population, while noting a 29% reduction (p=0.12) for the ITT population in the footer.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-b5af-740f-a5f5-cc716fe64761/17",
  "deckHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761",
  "deckJsonHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761.json",
  "deckAnchorHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761#slide-17",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.55,
        "x": 0.2,
        "y": 0.3
      },
      "kind": "chart",
      "text": "Line chart comparing PrimeC and Placebo ALSFRS-R scores over 180 days",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "533aefbf-51e9-4e84-8d19-a361070ecf3c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.15,
        "x": 0.69,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "* Per Protocol Population",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6c5a0672-3e61-4ac1-8623-516e724f0d7d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.03,
        "y": 0.93
      },
      "kind": "source-note",
      "text": "Note: A 29% reduction (p-0.12) in ALSFRS-R was observed in the ITT analysis",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f71955a3-d705-43ff-b23a-b3d3a04d76f4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.07,
        "y": 0.09
      },
      "kind": "title",
      "text": "PrimeC Significantly Attenuated Disease Progression by 37% in ALSFRS-R (p=0.03)",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ab113b6a-d56b-476a-b392-6f86a78716d2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.07,
        "y": 0.03
      },
      "kind": "title",
      "text": "Phase 2b Study Results – Per Protocol Population Analysis",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0a48719b-4eb7-4002-bdb7-574c1ebdf0b1",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Chart Selection Guide",
      "slug": "chart-selection-guide",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "46fbb259-083e-46c6-9f3c-6ba1985ec6bc",
      "evidence": "chart/line: Line chart comparing PrimeC and Placebo ALSFRS-R scores over 180 days",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 17,
      "from": 6,
      "beatId": "811b582e-32bd-4141-9a9d-a2d358e4ce91",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document presents PrimeC as a unique synergistic formulation with a powerful outcome, demonstrating statistically significant efficacy in key pre-clinical studies and promising results in Phase 2a and 2b clinical trials (p6-17).",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}